KO Cancer Act
The KO Cancer Act would dramatically increase and lock in additional funding for cancer research at the National Cancer Institute (NCI) from 2026 through 2030. Specifically, it would provide an annual appropriation equal to 25 percent of the NCI’s total FY 2022 appropriation, in addition to existing funding, with the money remaining available until expended. The bill also requires the Department of Health and Human Services to study and report within one year on why cancer drug shortages occur, including economic factors, supply chain issues, delays in drug development and FDA approval, and shortages of generics or biosimilars, and to include recommendations to address these shortages. The overall purpose is to elevate U.S. cancer research funding in response to mortality and burden, while also addressing the ongoing issue of drug shortages that affect treatment.
Key Points
- 1Short title: The act may be cited as the “Knock Out Cancer Act” or the “KO Cancer Act.”
- 2Funding increase for NCI: For fiscal years 2026–2030, the NCI would receive an amount equal to 25% of its total FY 2022 appropriation, in addition to current funding, with the new funds available until expended.
- 3Purpose of funding: The increased appropriation is described as aligning funding more closely with cancer mortality rates and the overall burden of cancer, supporting research, treatments, and potential innovations.
- 4Drug shortages study and report: The Secretary of Health and Human Services, via the FDA Commissioner, would study reasons for cancer drug shortages (economic factors, supply chain failures, development and approval delays, and shortage of generics/biosimilars) and must report findings to Congress within one year, including recommendations.
- 5Committee referrals: The bill was introduced in the House and referred to the Appropriations Committee and the Committee on Energy and Commerce for consideration of provisions within their jurisdiction.